We've found
9,144
archived clinical trials in
Ocular
We've found
9,144
archived clinical trials in
Ocular
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
Updated: 12/31/1969
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Analyses of Existing Framingham Data
Updated: 12/31/1969
Continued Analyses of Epidemiologic Risk Factors Using Existing Framingham Eye and Heart Study Data
Status: Enrolling
Updated: 12/31/1969
Analyses of Existing Framingham Data
Updated: 12/31/1969
Continued Analyses of Epidemiologic Risk Factors Using Existing Framingham Eye and Heart Study Data
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Annular Array Ultrasound in Ophthalmology
Updated: 12/31/1969
High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging
Status: Enrolling
Updated: 12/31/1969
Annular Array Ultrasound in Ophthalmology
Updated: 12/31/1969
High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Clinical Outcomes Following Treatment With SYSTANE® BALANCE
Updated: 12/31/1969
Clinical Evaluation Following Use of SYSTANE® BALANCE in Subjects With Lipid-Deficient Dry Eye
Status: Enrolling
Updated: 12/31/1969
Clinical Outcomes Following Treatment With SYSTANE® BALANCE
Updated: 12/31/1969
Clinical Evaluation Following Use of SYSTANE® BALANCE in Subjects With Lipid-Deficient Dry Eye
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Updated: 12/31/1969
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Status: Enrolling
Updated: 12/31/1969
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Updated: 12/31/1969
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Updated: 12/31/1969
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
